Taysha Gene Therapies, Inc.
TSHANASDAQHealthcare● Active
$5.43
$-0.07(-1.27%)
Market Cap$1.4B
P/E Ratio—
52W High$7.3
52W Low$2.25
Taysha Gene Therapies, Inc.（TSHA）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · TSHA · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $2.49M | $0.00M |
| Gross Profit | $9.77M | $8.33M | $15.45M | $0.01M | $0.00M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 0.60% | — |
| Operating Expenses | |||||
| R&D Expenses | $86.40M | $66.00M | $56.78M | $91.17M | $131.94M |
| G&A Expenses | $33.87M | $28.95M | $30.05M | $0.00M | $41.32M |
| Total Operating Expenses | $120.27M | $99.79M | $87.89M | $126.04M | $173.27M |
| Operating Income | ($110.50M) | ($91.46M) | ($72.44M) | ($126.03M) | ($173.27M) |
| Operating Margin %(computed) | — | — | -468.83% | — | — |
| Interest Income | $9.22M | $6.94M | $3.57M | $0.25M | $0.17M |
| Interest Expense | $0.06M | $0.10M | $5.00M | $3.80M | $1.43M |
| Income Before Tax | ($109.00M) | ($89.30M) | ($111.57M) | ($166.01M) | ($174.52M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($109.00M) | ($89.30M) | ($111.57M) | ($166.01M) | ($174.52M) |
| Net Margin %(computed) | — | — | -722.06% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| Wtd Avg Shares | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M |
| EBITDA | ($107.79M) | ($87.95M) | ($105.20M) | ($159.73M) | ($172.60M) |
| EBITDA Margin %(computed) | — | — | -680.84% | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Taysha Gene Therapies, Inc.
关于Taysha Gene Therapies, Inc.（TSHA）损益表
Taysha Gene Therapies, Inc.（TSHA）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，TSHA实现营收$0.01B，毛利润$0.01B（毛利率100.00%），净利润($0.11B)（净利率-1115.27%）。
常见问题
TSHA · 4 问Taysha Gene Therapies, Inc.（TSHA）2025财年营收为$0.01B，同比up17.3%。
TSHA revenueTSHA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09